Adopting a logical framework model to help achieve a balanced and healthy vaccine R&D portfolio

Vaccines are currently the 5th biggest therapy area with global sales for prophylactic and therapeutic vaccines to be ~ $30B, which is expected to increase to $45B by 2024. Immunization is globally recognized as one of the best investments to improve health, with impact lasting beyond saving 2-3M lives every year with benefits accrued over a lifetime. Enterprise value of any R&D company is a cumulative sum of its projects and proprietary technologies. Hence organizations need to continuously evaluate their portfolios to review the health of projects as changes in external environment may impact project viability. Simultaneously, addition of any new project in a company’s portfolio is a significant investment and needs to be evaluated using an objective multi-parametric framework. In this pursuit, Hilleman Labs, an equal joint venture by MSD and Wellcome Trust, has created a logical framework to evaluate potential vaccine candidates before they are added to the portfolio.